Healthcare

Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS…

4 months ago

Pharma Contract Manufacturing is the Quiet Reshoring Engine Investors Can’t Ignore

Black Book Flash Survey of VCs, PEs, Bankers, Analysts and Influencers Reveals Q4's Hottest Healthcare Investment NEW YORK CITY, NY…

4 months ago

KFSHRC to Participate as Strategic Partner in C3 Davos of Healthcare New York Summit

KFSHRC to Participate as Strategic Partner in C3 Davos of Healthcare ™ New York Summit A glimpse from KFSHRC’s presence…

4 months ago

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded…

4 months ago

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis…

4 months ago

Taiwan Showcases Smart Healthcare Breakthroughs at Taiwan Expo USA 2025

DALLAS, Aug. 31, 2025 /PRNewswire/ -- At Taiwan Expo USA 2025 in Dallas, the Smart Healthcare Pavilion, organized by the…

4 months ago

AI Clinical Documentation Adoption Surges, but ROI Hinges on Governance

Largest Health Systems AI 2025 comprehensive survey to date highlights adoption momentum and governance gap in U.S. hospitals CHICAGO, IL…

4 months ago

Could DEA Be Next? EPA Firings Spark Questions About DEA’s Accountability in MMJ’s Marijuana Licensing Delays

After the EPA dismissed employees who publicly criticized its leadership, attention is turning to the Drug Enforcement Administration's Diversion Control…

4 months ago

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke…

4 months ago